Allegro Diagnostics has assembled a strong leadership team with considerable depth of experience in development of genomic markers, genomic testing, clinical management of lung cancer and commercialization of novel biomarkers for cancer. The key members of the management team are:
Michael D. Webb
President and Chief Executive Officer
Mike has more than 25 years of experience in healthcare and life sciences. Most recently, he was the founder and CEO of Anchor Therapeutics, a venture-backed company focusing on developing pepducins, a new biology platform for drug discovery. Prior to founding Anchor, he was the CEO of EPIX Pharmaceuticals, Inc. from 1994 through 2005. During this period, EPIX grew from a venture-backed startup to the world leader in discovery and development of pharmaceuticals for diagnostic imaging with MRl, achieving worldwide approval for its lead product and completing numerous financings and corporate partnerships including an IPO on NASDAQ. Mr. Webb joined EPIX from CIBA, where he was most recently Senior Vice President, Worldwide Marketing and Strategic Planning of CIBA Diagnostics, responsible for global marketing, program management, corporate planning, business development and licensing. Prior to CIBA, Mr. Webb was a senior consultant at Booz, Allen & Hamilton, specializing in healthcare and life sciences.
Mr. Webb holds Bachelors degrees in Biochemistry and Economics from the University of Kansas, Summa Cum Laude and an MA in International Relations from Sussex University in the UK, completing his thesis on "Pharmaceuticals Policy and the World Health Organization." In addition, Mr. Webb holds an MBA degree with honors from the Kellogg Graduate School of Management at Northwestern University. He is a past chairman of the Massachusetts Biotechnology Council and currently serves on the boards of Anchor and Virtify, where he is Chairman of the Board. He also serves on the advisory boards of Deuteria Pharmaceuticals, Estern Medical, Wolfe Laboratories, the Kellogg Center for Biotechnology at Northwestern, the Institute for Advancing Medical Innovation at the University of Kansas and is a Senior Advisor to Johnston Blakely, a life sciences investment banking firm.
Acting Chief Financial Officer
In addition to his role at Allegro Diagnostics, Bill is also a Sr. Analyst/Controller at Kodiak Venture Partners and the CFO of Lumicell Diagnostics. He is responsible for the financial reporting and monitoring of the Kodiak portfolio companies, Kodiak funds, and various operational activities at Kodiak. Prior to joining Kodiak Venture Partners, Bill was a Fund Analyst at Summit Partners, and a Senior Associate at PricewaterhouseCoopers. Bill is also a Certified Public Accountant in Massachusetts.
Bill received his M.B.A. from Boston College’s Carroll School of Management and a B.A. in Economics-Accounting from the College of the Holy Cross.
Duncan Whitney, PhD
Senior Vice President, Research, Development and Technical Operations
Duncan Whitney has over 20 years of experience developing and commercializing technologies in emerging and mid-sized Life Sciences companies, with an emphasis on diagnostics test development in the last 10 years. Dr. Whitney’s experience and leadership further Allegro Diagnostics’ goals in lung-cancer biomarker development and optimization, commercial product development and launch, and development of a strong product pipeline. Prior to joining Allegro, Dr. Whitney served as Chief Scientific Officer of Progenika Inc., a microarray-based clinical diagnostics company. Previous roles include, VP of R&D at U.S. Genomics Inc., developing single-molecule detection strategies and assays for both protein and microRNA targets; VP of Technology Development at Exact sciences Corp, a company focused on colon cancer diagnostics and several years in R&D leadership roles at PerSeptive Biosystems (now part of Life Technologies). Dr. Whitney received his PhD from the Massachusetts Institute of Technology and his B.A. from Colby College.
Avrum Spira, MD, MSc
Scientific and Clinical Advisor
Dr. Avrum Spira is Alexander Graham Bell Professor in Health Care Entrepreneurship and Chief of the Division of Computational Biomedicine in the Department of Medicine at the Boston University School of Medicine. Additionally, he serves as Director of the Bioinformatics and Systems Biology Program at the Boston University School of Medicine's Pulmonary Center. He is an attending physician at the Medical Intensive Care Unit and with the Pulmonary/Critical Care Interventional service at Boston Medical Center. Dr. Spira's laboratory research interests focus on applying high-throughput genomic and bioinformatic tools to the translational study of lung cancer and emphysema. He is funded as a Principal Investigator through the NIH and the Doris Duke Charitable Foundation. Dr. Spira received his medical degree from McGill University and did his internship and residency at the University of Toronto. He did his fellowship with Boston University. Dr. Spira received a Master's degree in Bioinformatics from the College of Engineering at Boston University.